**Patient Details**
- **DOB:** 03/15/1959
- **Age (y/m/d):** 62/00/30
- **Gender:** M
- **Patient ID:**

**Specimen Details**
- **Date collected:** 04/14/2021 0000 Local
- **Date received:** 04/14/2021
- **Date entered:** 04/14/2021
- **Date reported:** 04/14/2021 0855 ET

**Physician Details**
- **Ordering:**
- **Referring:**
- **ID:**
- **NPI:**

---

**Ordered Items**
- **SARS-CoV-2, NAA**

### TESTS
<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Not Detected</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include RT-PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

**SARS-CoV-2, NAA 2 DAY TAT**

Performed

<table>
<thead>
<tr>
<th>01</th>
<th>BN</th>
<th>LabCorp Burlington</th>
<th>Dir: Sanjai Nagendra, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1447 York Court, Burlington, NC 27215-3361</td>
<td></td>
</tr>
<tr>
<td>02</td>
<td>$$</td>
<td>Testmaster Testing</td>
<td>Dir: Report Testing, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3060 S Church Street, Burlington, NC 27215</td>
<td></td>
</tr>
</tbody>
</table>
### General Comments & Additional Information

**Clinical Info:** DETECTED

**Ordered Items**

SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Detected Abnormal</td>
<td>Not Detected</td>
<td>01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patients who have a positive COVID-19 test result may now have treatment options. Treatment options are available for patients with mild to moderate symptoms and for hospitalized patients. Visit our website at https://www.labcorp.com/COVID19 for resources and information.

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include RT-PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

### Ordered Items

- **SARS-CoV-2, NAA**
  
<table>
<thead>
<tr>
<th>TAT</th>
<th>LAB Details</th>
<th>Dir:</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 BN</td>
<td>LabCorp Burlington</td>
<td>Sanjai Nagendra, MD</td>
</tr>
<tr>
<td></td>
<td>1447 York Court, Burlington, NC 27215-3361</td>
<td></td>
</tr>
<tr>
<td>02 $$</td>
<td>Testmaster Testing</td>
<td>Report Testing, PhD</td>
</tr>
<tr>
<td></td>
<td>3060 S Church Street, Burlington, NC 27215</td>
<td></td>
</tr>
</tbody>
</table>

For inquiries, the physician may contact Branch: 800-222-7566 Lab: 336-436-2762
## Patient Report

**Specimen ID:** 104-988-9015-0  
**Act #:** 90000999

**Control ID:**  
**Acct #:** 90000999  
**Phone:** (336) 436-8645

**Rte:** 00

**LabCorp Test Master**  
**Test Account**  
**5450 Millstream Road**  
**MCLEANSVILLE NC 27301**

---

**Sample Report 3, 139900**

### Patient Details
- **DOB:** 07/04/1976
- **Age (y/m/d):** 04/09/10
- **Gender:** M
- **Patient ID:**

### Specimen Details
- **Date collected:** 04/14/2021 0000 Local
- **Date received:** 04/14/2021
- **Date entered:** 04/14/2021
- **Date reported:** 04/14/2021 0855 ET

### Physician Details
- **Ordering:**
- **Referring:**
- **ID:**
- **NPI:**

### Date Issued: 04/14/21 0859 ET

**FINAL REPORT**

---

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 800-222-7566

---

**General Comments & Additional Information**

**Clinical Info:** INDETERMINATE

**Ordered Items**

SARS-CoV-2, NAA

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2, NAA</td>
<td>Indeterminate Abnormal</td>
<td>Not Detected</td>
<td>01</td>
<td>02</td>
<td></td>
</tr>
</tbody>
</table>

We are UNABLE to reliably determine a result for the specimen due to the inconsistent amplification of all of the required SARS-CoV-2 components from the specimen submitted. If clinically indicated, please recollect an additional specimen for testing.

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include RT-PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

SARS-CoV-2, NAA 2 DAY TAT

Performed

<table>
<thead>
<tr>
<th>Test</th>
<th>Lab</th>
<th>Dir</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>BN LabCorp Burlington</td>
<td>Sanjai Nagendra, MD</td>
</tr>
<tr>
<td>1447 York Court, Burlington, NC 27215-3361</td>
<td></td>
<td></td>
</tr>
<tr>
<td>02</td>
<td>$$ Testmaster Testing</td>
<td>Report Testing, PhD</td>
</tr>
<tr>
<td>3060 S Church Street, Burlington, NC 27215</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For inquiries, the physician may contact **Branch:** 800-222-7566 **Lab:** 336-436-2762

---

© 1995-2021 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00